However, in advanced tumor stages, when cancer cells engage T cell checkpoints including PD-1 and CTLA4 [32], stimulation of GITR might be disadvantageous for the tumor, as stimulation of GITR also inhibits the suppressive properties on regulatory T cells [33]. The gene discussed is TNFRSF18; the disease is neoplasm.